PD-1/PD-L1在甲状腺癌中的作用及机制研究进展  

Research Progress in the Role and Mechanism of PD-1/PD-L1 in Thyroid Carcinoma

作　　者：徐振国 聂春磊[1] 张杰武[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《肿瘤学杂志》2017年第10期899-903,共5页Journal of Chinese Oncology

基　　金：海燕科研基金(省科技厅公关计划)(JJZD2017-03)

摘　　要：肿瘤细胞中表达的程序性死亡配体(PD-L1)是新兴的生物标志物,它在抗肿瘤免疫治疗中具有非常重要的作用。程序性死亡受体1(programmed cell death-1,PD-1)与其配体PD-L1属于CD28/B7家族,是一对共刺激分子,具有负性调控作用。最新研究发现,PD-L1与PD-1的异常表达与多种癌症的发生、侵袭、转移相关。全文就PD-1/PD-L1生物学作用以及其在甲状腺癌的发生、发展中的机制研究进展、PD-1/PD-L1信号通路抑制剂及其未来在甲状腺癌靶向治疗应用前景进行综述。Programmed cell death-ligand 1（PD-L1） expressed in tumor cells is a emerging biomarker,playing a pivotal role in anti-tumor immunotherapy. Programmed cell death-1（PD-1）and its ligand PD-L1,belonging to CD28/B7 family,are a pair of costimulatory molecules with function to negative regulate immune response to tumor. The latest studies have found that the abnomal expression of PD-L1 and PD-1 is associated with the occurrence,invasion,and metastasis of various malignant tumors. In this paper,we reviewed the biological function of PD-1/PD-L1 and its mechanism in the occurrence and progression of thyroid carcinoma,with a special focus on PD-1/PD-L1 signaling pathway inhibitor and its application in thyroid cancer targeted therapy in the future.

关 键 词：PD-1/PD-L1 甲状腺癌 分子通路 侵袭性 

分 类 号：R736.1[医药卫生—肿瘤]